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Human tauopathies, such as Alzheimer’s disease (AD), have been widely studied in
transgenic mice overexpressing human tau in the brain. The longest brain isoforms of
Tau in mice and humans show 89% amino acid identity; however, the expression of the
isoforms of this protein in the adult brain of the two species differs. Tau 3R isoforms are
not present in adult mice. In contrast, the adult human brain contains Tau 3R and also
Tau 4R isoforms. In addition, the N-terminal sequence of Tau protein in mice and humans
differs, a Tau peptide (residues 17–28) being present in the latter but absent in the former.
Here we review the main published data on this N-terminal sequence that suggests that
human and mouse Tau proteins interact with different endogenous proteins and also
show distinct secretion patterns.
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INTRODUCTION
The microtubule-associated protein Tau is mainly expressed in neurons (Weingarten et al., 1975;
Drubin and Kirschner, 1986). Tau promotes the assembly and stabilization of microtubules (for a
review, see Avila et al., 2004). However, it has recently been suggested that rather than stabilizing
the microtubules, Tau allows them to have labile domains (Baas and Qiang, 2019). In addition,
and taking into account the subcellular localizations of Tau outside the axonal compartment, new
functions have been proposed for this protein in dendrites (involvement in synaptic plasticity
and regulation of NMDA/AMPA receptors), the nucleus (regulation of heterochromatin stability
and integrity of cytoplasmic and nuclear RNA) and the membrane (interaction con F-actin and
membrane proteins; for a review, see Sotiropoulos et al., 2017).
The hyperphosphorylation and aggregation of Tau in neurons is a common pathological
hallmark of several neurodegenerative diseases known as tauopathies, Alzheimer’s disease
(AD) being the most prevalent (Spillantini and Goedert, 2013). AD is characterized by the
accumulation of extracellular plaques of β-amyloid peptide and intracellular neurofibrillary
tangles (NFTs) formed by aggregated and hyperphosphorylated Tau protein. The amyloid
cascade theory proposes that β-amyloid drives Tau phosphorylation and then Tau forms
filaments and these filaments accumulate in NFTs (Selkoe and Hardy, 2016). The hypothesis
suggests that β-amyloid accumulation precedes altered Tau metabolism. In addition, it has
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been demonstrated that a reduction of endogenous Tau
ameliorates β-amyloid-induced deficits in AD (Rapoport et al.,
2002; Santacruz et al., 2005; Roberson et al., 2007; Shipton et al.,
2011). Under pathological conditions, the hyperphosphorylation
of Tau protein prevents its binding to microtubules, resulting
in its accumulation in the cytosol and consequent formation
of intracellular NFTs. Aggregated Tau present in tauopathies
does not seem to be the main toxic species. Instead, neuronal
toxicity appears to be caused by smaller soluble aggregates
or by specific conformations of Tau protein. In recent years,
certain Tau conformations, called strains, have been linked to
specific tauopathies (Sanders et al., 2014). Tau also accumulates
in microglia and astrocytes in several of these conditions (Buée
and Delacourte, 1999; Kovacs et al., 2016; Ferrer et al., 2018).
The prion-like hypothesis proposes that Tau propagates from
the entorhinal cortex and hippocampus to the cerebral cortex,
thereby explaining in part the progression of AD (Braak and
Braak, 1991). Tau is secreted and this extracellular form is taken
up by neurons and glial cells (Gómez-Ramos et al., 2006; Calafate
et al., 2015), thus contributing to the cell-to-cell spread of the
protein (Holmes and Diamond, 2014; Medina and Avila, 2014).
Genetically altered mouse models have been widely used to
study Tau metabolism (see https://www.alzforum.org/research-
models) and have greatly contributed to our understanding of
disease-related mechanisms. Furthermore, they are valuable for
the evaluation of novel therapeutic approaches. Nevertheless,
in addition to distinct splicing processes, mouse and human
Tau protein show other differences. Here we focus on recent
data suggesting that the N-terminal end of Tau protein explains
why none of the murine models fully reproduces the complete
spectrum of AD or related tauopathies.
DIFFERENCES BETWEEN HUMAN AND
MURINE TAU GENE
Human tau (chromosome 17) spans 134 kb while murine tau
(chromosome 11) stretches across 100 kb (for a review, see
Poorkaj et al., 2001; Figure 1A). The genomic context for the
microtubule-associated protein tau gene (MAPT) in humans
and mice is similar (Figure 1B). MAPT through alternative
splicing, give rise to distinct Tau isoforms in the central nervous
system (CNS; Goedert et al., 1989; Andreadis et al., 1992). In
the adult CNS, alternative splicing produces six distinct Tau
isoforms, which differ in the presence or absence of exons 2,
3 and 10. While exon 2 can appear alone, exon 3 never appears
independently of exon 2. Exon 10 encodes one of the four repeat
sequences that form the microtubule-binding domain (MBD).
Those isoforms that carry exon 10 result in Tau with four
repeated microtubule-binding sequences (Tau 4R), while those
without this exon have only three (Tau 3R; Figure 1D). The
expression of these Tau isoforms is regulated by development.
Tau 3R isoforms are present in early stages of development, while
Tau 4R are found mainly in adults (for a review, see Avila et al.,
2004; Wang and Mandelkow, 2016).
The main function of tau is to promote the polymerization of
tubulins (Weingarten et al., 1975) and prevents their instability
by its binding to microtubules (Drechsel et al., 1992). The
Tau 4R isoform promotes microtubule assembly faster than
Tau 3R (Goedert and Jakes, 1990). This observation suggests
that the Tau 3R protein modulates brain development by
decreasing the stability of microtubules. The expression of Tau
3R protein during development, as well as the absence of
Tau 4R in the fetal human brain (Goedert et al., 1989; Kosik
et al., 1989; Goedert and Jakes, 1990) support this notion.
In the adult human brain, Tau 3R and Tau 4R isoforms
are present in the same proportion (Avila et al., 2004). In
addition to regulation through splicing, Tau phosphorylation
is controlled during development, being higher in fetal
neurons and decreasing with age (Brion et al., 1993). Tau
phosphorylation during development correlates with the period
of active neurite outgrowth, a process that requires a dynamic
microtubule network.
The expression of Tau isoforms in the adult mice brain
differs from humans. The Tau 3R isoform is not present in
adult mice (Brion et al., 1993; Spillantini and Goedert, 1998).
In this regard, adult hippocampal neurogenesis in mice is
characterized by an unusual feature, namely Tau 3R is the main
isoform present in newborn neurons in the hippocampal dentate
gyrus (Bullmann et al., 2007) and in the subventricular zone
(SVZ; Fuster-Matanzo et al., 2009). Doublecortin (DCX) is a
microtubule-associated protein expressed in neural progenitor
cells. DCX+ cells give rise to new neurons in the adult
brain. DCX-positive neuroblasts express the Tau 3R isoform
and Tau is also found in a phosphorylated form (Fuster-
Matanzo et al., 2009). During the processes of differentiation
to adult neurons, there is a progressive change towards
Tau 4R in mature granule cells (Bullmann et al., 2007).
These data support the notion that axonal outgrowth that
takes place in these neuroblast DCX+ requires a dynamic
microtubule network and that Tau protein contributes to
this dynamic cytoskeleton. In this regard, neuronal polarity
and axonal outgrowth take place during adult neurogenesis,
microtubules express Tau isoforms with less affinity for
microtubules as Tau 3R is hyperphosphorylated. Interestingly, it
has been proposed that adult neurogenesis recapitulates neuronal
development (Ming and Song, 2011) as Tau phosphorylation
is higher in fetal neurons (Brion et al., 1993) and Tau
3R isoforms are found during early developmental stages
(Avila et al., 2004).
In addition to the splicing differences between human and
mouse Tau protein, intron 9 (between exon 9 and 10) of human
tau has a region that can give rise to the expression of a
protein known as saitohin (Conrad et al., 2002; Figure 1B).
Saitohin is not present in mice. In this regard, although a
homologous sequence is found in the mouse gene, the absence
of an open reading frame in mice prevents Saitohin expression
(Conrad et al., 2004).
DIFFERENCES BETWEEN HUMAN AND
MURINE TAU PROTEIN
Tau of distinct origins shows some variability in primary
sequence—variability in the N-terminal end being greatest
(Nelson et al., 1996). Although mouse and human Tau
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FIGURE 1 | (A) Human and murine tau organization. Integrative Genomics viewer (using Human19 and Mouse mm10 genome versions) has been used to show the
longest central nervous system (CNS) splicing isoforms (Tau 4R). Exons are shown by a vertical bar. Distances between exons are proportional to the sizes of the
introns. Exons that undergo alternative splicing in the CNS: 2, 3 and 10 are indicated. It should be noted that although human and murine tau are similar size in the
figure, the former covers 134 kb while the latter extends across 100 kb. The chromosomic localizations (red boxes) are also shown. (B) The genomic context for
microtubule-associated protein tau gene (MAPT) in human chromosome 17 and mouse chromosome 11 are shown using data from The National Center for
Biotechnology Information (NCBI; https://www.ncbi.nlm.nih.gov/). KANSL1, KAT8 regulatory NSL complex subunit 1; CRHC1, corticotropin-releasing hormone
receptor 1; MAPT, Tau; STH, saitohin. (C) Sequence alignment of human Tau (entry UniProt number P10636-8) and mouse Tau (entry UniProt number sequence
P10637-2) using the Clustal Omega program from the UniProt website. N-terminal domains, as well as microtubule-binding domains (MBD), are shown. In the figure,
the same amino acids (*), while conservative amino acids (:) or less conservative ones (.) are highlighted. (D) A scheme of Tau isoforms present in the CNS. Six main
transcripts are generated from a single gene. These isoforms are generated by alternative splicing of exons 2, 3, and 10. Exon 3 never appears independently of
exon 2. Exons 1, 4, 5, 7, 9, 11, 12 and 13 are constitutive. Alternative splices of exons 2 (light orange), 3 (orange), and 10 (light blue) are shown in panels (C,D).
sequences are similar, the latter contains 11 amino acids in
the N-terminal end that are absent in mice (Figure 1C).
These amino acids probably affect some functions in which
Tau is involved. Tau adopts the so-called ‘‘paperclip’’ folding
in solution, and the N- and C-terminal domains fold onto
the microtubule-binding repeat domains (Carmel et al., 1996;
Jicha et al., 1997). The presence of residues 17–28 in humans,
making the N-terminal end longer than in mice, could have
implications for the intramolecular interaction between the
N- and C-terminal ends of the protein and the microtubule-
binding repeat domains. Given the difference in the N-terminal
sequence of human and mouse Tau, it can be speculated
that the latter would be less likely to adopt this pathological
‘‘paperclip’’ conformation, something that has been already
proposed (Ando et al., 2011).
Figure 1C shows that the domain around tyrosine-18 differs
between the two species. Tyrosine-18 is phosphorylated by
Src-family non-receptor tyrosine kinase Fyn (Lee et al., 1998,
2004) and Tyrosine-18 phosphorylation modulates NMDA
receptor in primary neuronal culture (Miyamoto et al., 2017).
Interestingly, Tau mediates the targeting of Fyn to postsynaptic
dendrites (Ittner et al., 2010). At present, it is not clear whether
tyrosine-18 phosphorylation is increased or decreased in human
Tau compared with the murine form of the protein. Given
that the NMDA receptor may be necessary for the toxic effect
of the β-amyloid peptide (Ittner et al., 2010), differences in
tyrosine-18 phosphorylation in mouse and human tau could be
relevant. Of note, proline residues Pro213, Pro216, and Pro219,
which are important for the binding of Tau protein to Fyn (Lau
et al., 2016), are present in both human and murine Tau (see
Figure 1).
The N-terminal projection region of Tau protein, which
protrudes around 19 nm from the microtubule surface
(Hirokawa et al., 1988), allows interaction with other proteins.
Several N-terminal Tau interaction partners have been identified.
The first interaction described was with the neural plasma
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membrane through its N-terminal projection domain (Brandt
et al., 1995), thereby suggesting that Tau was a mediator
of microtubule-plasma membrane interactions and thus plays
an important role in neuritic development. Recently, a study
using a heterologous yeast system has revealed that Tau
interacts with Annexin A2 in a Ca2+-dependent manner via the
N-terminal projection domain (Gauthier-Kemper et al., 2018).
This observation, therefore, suggests that Tau links microtubules
to the axonal plasma membrane through this domain. The same
study described that Tau also interacts with Annexin A6, which
localizes to the axon initial segment (AIS), where the binding
of Tau may lead to its retention in the axonal compartment
(Gauthier-Kemper et al., 2018).
Another approach to study the function of the N-terminal end
of Tau protein, specifically the role of amino acids 18–28 present
in the human sequence (Figure 1C), involved removing these
amino acids from the full length recombinant human protein
and then performing glutathione-S transferase (GST) pull-down
assays and mass spectrometry analysis. Thus, it was found
that the human-specific N-terminal Tau motif interacts with
neuronal proteins such as Synapsin-1 and Synaptotagmin-1
(proteins involved in synaptic transmission), proteins of the
14–3–3 family, and Annexin A5 (Stefanoska et al., 2018).
To test for proteins that specifically and only bind to
human Tau residues 16–26 (not present in murine Tau), a
column containing this peptide linked to Sepharose was used
to study human brain proteins that bound to the resin from
control subjects and from patients with Alzheimer disease.
Creatine kinase-B (CK-B), gamma-enolase and glyceraldehyde
3-phosphate dehydrogenase were observed to bind to this human
Tau peptide. Interestingly, CK-B from brain extracts taken from
patients with AD did not bind to Tau (Hernández et al., 2019).
This observation could be attributable to the oxidation of CK-B
in this disease (Hernández et al., 2019). CK-B is a brain isoform
that phosphorylates creatine in the presence of ATP (Wallimann
et al., 1992), and enolase and glyceraldehyde 3-phosphate
dehydrogenase are critical enzymes in the glycolytic pathway.
These proteins are related to energetic processes and can have
a high impact on neuronal functions that require energy.
Moreover, the brain is highly susceptible to oxidative imbalance,
and changes in the level of ATP may induce neurodegeneration
(Wang et al., 2014). The CK-B/phosphocreatine complex may
supply the ATP required for axonal transport under conditions
in which this energy supply is interrupted (Wallimann et al.,
2011). In fact, creatine protects cortical axons from energy
depletion in vitro (Shen and Goldberg, 2012). Regarding the
other proteins, enolase moves along the axon (Brady and Lasek,
1981) and glyceraldehyde 3-phosphate dehydrogenase has been
implicated in rapid axonal transport (Zala et al., 2013). These
data suggest that the presence of this domain (residues 16–26)
in human Tau supports energy supply by glycolysis in times
of low oxygen levels and may explain, at least in part, the
decrease in glucose metabolism observed in AD due to altered
Tau metabolism (Butterfield and Halliwell, 2019). Given that
these studies have been carried out with the peptide that is
present in human but not murine Tau, it is reasonable to
propose that either these interactions do not take place in the
latter or that the interaction of these proteins with murine
Tau differs.
DIFFERENCES BETWEEN HUMAN AND
MURINE TAU SECRETION
Tau is mainly an intracellular protein, although it is also present
in brain interstitial fluid (for a review, see Yamada, 2017).
Tau protein is secreted in vivo, and this process appears to be
regulated in physiological conditions andmodulated by neuronal
activity (Pooler et al., 2013). The exact mechanism of Tau
release is unclear. However, several studies have demonstrated
the extracellular presence of vesicle-bound and soluble free
Tau (Saman et al., 2012; Kanmert et al., 2015; Wang et al.,
2017). Although it is not clear how Tau can localize at the
cell membrane, several reports demonstrate its presence in
this structure (Brandt et al., 1995; Arrasate et al., 2000). This
localization may indeed favor its further secretion. In addition,
it should be noted that neuronal death can result in the release
of Tau into the extracellular space, thereby contributing to
extracellular Tau in pathological conditions.
The abnormal accumulation of intracellular Tau can be
mediated through the cell-to-cell propagation of seeds of the
protein. This observation has given rise to the hypothesis of
a prion-like transmission to explain the propagation of the
main neuropathological hallmarks of AD (Goedert et al., 2010).
This hypothesis suggests that pathology begins in a part of the
brain and spreads through this organ over time, for example
from the entorhinal cortex (Braak and Braak, 1991) or/and
from the locus ceruleus (Braak and Del Tredici, 2011). The
nature of the Tau species involved in secretion, spreading and
uptake, as well as the apparent selectivity that could explain
why certain neurons are affected while others are not, remains
unclear. Greater knowledge of this process will contribute to the
development of new therapeutic approaches focused on stopping
the spread of the disease and of new approaches to facilitate
early diagnosis. Interestingly, human Tau lacking N-terminal
amino acids 18–28 is less efficiently secreted than full-length
Tau upon overexpression in Cos7 cells (Sayas et al., 2019).
That study demonstrated that the sequence containing human
Tau residues 18–28 acts as a binding motif for End Binding
proteins and that this interaction facilitates Tau secretion to the
extracellular space (Sayas et al., 2019). Although a comparative
study with murine Tau protein that lacks this sequence at the
N-terminal end has not been carried out, differences with the
human protein would be expected. However, this does not
imply that murine Tau is not secreted since the protein is
also found in the extracellular compartment of wild-type mice
(Yamada et al., 2011).
CONCLUDING REMARKS
Given that decreased Tau expression is neuroprotective,
strategies to achieve a reduction in its expression are among
the most promising approaches for the development of AD
therapeutic drugs (for a review, see Jadhav et al., 2019). In this
regard, the evaluation of these strategies must first be validated
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in murine models. However, as shown in this mini-review, Tau
metabolism in mice differs from that in humans, not only in the
splicing process (presence of Tau 3R in adult humans but not in
mice) but also in the primary sequence, mainly in the N-terminal
end. These differences may limit the success of murine genetic
models and explain why they do not fully reproduce the complete
spectrum of AD pathology or related tauopathies.
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